论文部分内容阅读
目的:通过新固肠止泻丸体外抑菌实验来探讨其治疗UC的机制。方法:采用微孔二倍稀释法测定金黄色葡萄球菌、大肠埃希菌、铜绿假单孢菌、福氏志贺菌、伤寒沙门菌、鼠伤寒沙门菌、肠炎沙门菌、肺炎克雷伯菌、变形杆菌、白色假丝酵母菌等11株菌株,标准菌株的MIC、MBC以及360株临床株的MIC及MBC。结果:新固肠止泻丸体外抗菌试验结果分析显示:对实验所选的11株肠道感染菌标准株均有抑菌作用(MIC 18.5～150mg/ml)。除铜绿假单孢菌和白色假丝酵母菌外(MBC>300mg/ml),对其他9株标准菌有杀菌作用(MBC:37.5～150mg/ml)。对340株临床分离肠道感染菌均有一定的抑菌和杀菌作用(MIC 9.4～300mg/ml;MBC 18.8～300mg/ml)。结论 :实验结果表明,新固肠止泻丸对UC大鼠模型具有一定的治疗作用;这可能与对引发UC的肠道菌群等有一定的抑制作用有关。
OBJECTIVE: To explore the mechanism of UC in treating Bacillus subtilis by antibacterial experiment in vitro. Methods: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Shigella flexneri, Salmonella typhi, Salmonella typhimurium, Salmonella enteritidis, Klebsiella pneumoniae , Proteus, Candida albicans and other 11 strains, MIC and MBC of standard strains and MIC and MBC of 360 clinical strains. Results: The results of in vitro antibacterial test of Xinzhu Zhixie Pill showed that all of the 11 strains of enteric bacteria selected in the experiment had antibacterial activity (MIC 18.5-150 mg / ml). In addition to Pseudomonas aeruginosa and Candida albicans (MBC> 300mg / ml), the other 9 strains of bacteria have bactericidal effect (MBC: 37.5 ~ 150mg / ml). There were some antibacterial and bactericidal effects on 340 clinical isolates of intestinal tract infection (MIC 9.4 ~ 300mg / ml; MBC 18.8 ~ 300mg / ml). Conclusion: The experimental results show that the new Gumin Zhixie Pill has a certain therapeutic effect on the UC rat model; this may be related to the initiation of UC intestinal flora and some have a inhibitory effect.